The microenvironment in antibiotic susceptibility testing

IF 2.2 4区 医学 Q4 IMMUNOLOGY
Apmis Pub Date : 2024-04-02 DOI:10.1111/apm.13405
Niels Høiby, Claus Moser, Oana Ciofu
{"title":"The microenvironment in antibiotic susceptibility testing","authors":"Niels Høiby,&nbsp;Claus Moser,&nbsp;Oana Ciofu","doi":"10.1111/apm.13405","DOIUrl":null,"url":null,"abstract":"<p>Antibiotic susceptibility testing (AST) by agar diffusion has been repeatedly standardized and, in most cases, gives results which predict clinical success when antibiotic treatment is based on such results. The formation of the inhibition zone is due to a transition from planktonic to biofilm mode of growth. The kinetics of the interaction of antibiotics with bacteria is similar during AST by agar diffusion and during administration of antibiotics to the patients. However, the Mueller-Hinton agar (MHA) recommended for AST agar diffusion test is fundamentally different from the composition of the interstitial fluid in the human body where the infections take place and human cells do not thrive in MH media. Use of RPMI 1640 medium designed for growth of eucaryotic cells for AST of <i>Pseudomonas aeruginosa</i> against azithromycin results in lower minimal inhibitory concentration, compared to results obtained by MHA. The reason is that the RPMI 1640 medium increases uptake and reduces efflux of azithromycin compared to MHA. During treatment of cystic fibrosis patients with azithromycin, mutational resistance occur which is not detected by AST with MHA. Whether this is the case with other antibiotics and bacteria is not known but it is of clinical importance to be studied.</p>","PeriodicalId":8167,"journal":{"name":"Apmis","volume":"132 12","pages":"985-991"},"PeriodicalIF":2.2000,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apm.13405","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Apmis","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/apm.13405","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Antibiotic susceptibility testing (AST) by agar diffusion has been repeatedly standardized and, in most cases, gives results which predict clinical success when antibiotic treatment is based on such results. The formation of the inhibition zone is due to a transition from planktonic to biofilm mode of growth. The kinetics of the interaction of antibiotics with bacteria is similar during AST by agar diffusion and during administration of antibiotics to the patients. However, the Mueller-Hinton agar (MHA) recommended for AST agar diffusion test is fundamentally different from the composition of the interstitial fluid in the human body where the infections take place and human cells do not thrive in MH media. Use of RPMI 1640 medium designed for growth of eucaryotic cells for AST of Pseudomonas aeruginosa against azithromycin results in lower minimal inhibitory concentration, compared to results obtained by MHA. The reason is that the RPMI 1640 medium increases uptake and reduces efflux of azithromycin compared to MHA. During treatment of cystic fibrosis patients with azithromycin, mutational resistance occur which is not detected by AST with MHA. Whether this is the case with other antibiotics and bacteria is not known but it is of clinical importance to be studied.

Abstract Image

抗生素药敏试验中的微环境
通过琼脂扩散法进行的抗生素药敏试验(AST)已被反复标准化,在大多数情况下,根据这些结果进行抗生素治疗时,可预测临床治疗是否成功。抑制区的形成是由于从浮游生物生长模式过渡到生物膜生长模式。在琼脂扩散法检测抗生素与细菌相互作用的动力学过程中,以及在给患者使用抗生素的过程中,抗生素与细菌相互作用的动力学过程是相似的。然而,AST 琼脂扩散试验推荐使用的穆勒-欣顿琼脂(MHA)与发生感染的人体间质的成分有本质区别,人体细胞在 MH 培养基中无法生长。使用专为真核细胞生长设计的 RPMI 1640 培养基进行铜绿假单胞菌对阿奇霉素的 AST 试验,其最小抑菌浓度比用 MHA 得出的结果要低。原因是与 MHA 相比,RPMI 1640 培养基能增加阿奇霉素的吸收并减少其外流。在用阿奇霉素治疗囊性纤维化患者的过程中,会出现变异耐药性,而用 MHA 进行 AST 检测则检测不到。其他抗生素和细菌是否也会出现这种情况尚不清楚,但对临床具有重要的研究意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Apmis
Apmis 医学-病理学
CiteScore
5.20
自引率
0.00%
发文量
91
审稿时长
2 months
期刊介绍: APMIS, formerly Acta Pathologica, Microbiologica et Immunologica Scandinavica, has been published since 1924 by the Scandinavian Societies for Medical Microbiology and Pathology as a non-profit-making scientific journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信